Stelmack T R
VA Medical Center, Chicago, IL 60612.
J Am Optom Assoc. 1987 Sep;58(9):716-21.
Open-angle glaucoma is a non-curable, blinding disease which has its best prognosis when management begins at its earliest onset. Recent studies, such as those demonstrating axonal loss before functional or physical changes occur, will have an effect on the current standard of management. This includes indications for initiating treatment as well as what constitutes controlled intraocular pressure. Pharmacological management is often difficult due to drug tolerance and compliance problems. Some types of secondary open angle glaucomas respond very poorly to treatment. Hence, an accurate diagnosis is imperative to proper management. Principles underlying pharmacological management are discussed. When pharmacological management fails, laser and/or surgical intervention is required to prevent further vision loss.
开角型青光眼是一种无法治愈的致盲性疾病,若在发病初期就开始治疗,其预后最佳。近期的研究,比如那些表明在功能或物理变化发生之前就存在轴突损失的研究,将会对当前的治疗标准产生影响。这包括开始治疗的指征以及眼压得到控制的标准。由于药物耐受性和依从性问题,药物治疗往往很困难。某些类型的继发性开角型青光眼对治疗反应很差。因此,准确的诊断对于正确的治疗至关重要。文中讨论了药物治疗的基本原则。当药物治疗失败时,需要进行激光和/或手术干预以防止视力进一步丧失。